| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701980 | Journal of Thoracic Oncology | 2017 | 16 Pages |
Abstract
In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel. Mechanisms of acquired resistance to first-line tyrosine kinase inhibitor therapy should be elucidated to guide selection of second-line treatment for these patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Chee Khoon PhD, Johnathan M.B.B.S., Sally MSc, Matthew PhD, Val MStat, Tony MD, James Chih-Hsin PhD,